PD-1/PD-L1 antibodies have been widely used in the treatment of NSCLC, but they are often accompanied with unpredicted side effects, and many patients cannot derive survival benefits with high medical expenses (4, 11, 22). Here, CD274 is linked to non-small cell lung carcinoma.